Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE

Journal of Neurology

Volumn 262, Issue 2, 2015, Pages 326-336

  Kaufman, Michael ^a   Cree, Bruce A C ^b   De Sèze, Jerome ^c   Fox, Robert J ^d   Gold, Ralf ^e   Hartung, Hans Peter ^f   Jeffery, Douglas ^g   Kappos, Ludwig ^h   Montalbán, Xavier ⁱ   Weinstock Guttman, Bianca ^j   Ticho, Barry ^k   Duda, Petra ^l   Pace, Amy ^m   Campagnolo, Denise ^m  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HÔPITAL CIVIL   (France)

^d LERNER RESEARCH INSTITUTE   (United States)

^e ST JOSEF HOSPITAL   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g Piedmont Healthcare   (United States)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j JACOBS NEUROLOGICAL INSTITUTE   (United States)

^k PFIZER INC   (United States)

^l AVI BIOPHARMA INC   (United States)

^m BIOGEN   (United States)

more..

Author keywords

Gadolinium enhancing lesions; MRI; Multiple sclerosis; Natalizumab; Treatment interruption

Indexed keywords

GADOLINIUM; NATALIZUMAB; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; CLINICAL TRIAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RADIOGRAPHY;

ADULT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; RECURRENCE;

EID: 84925532857     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7558-6     Document Type: Article

References (32)

1. Belachew S, Phan-Ba R, Bartholomé E, Delvaux V, Hansen I, Calay P, Hafsi KE, Moonen G, Tshibanda L, Vokaer M (2011) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 18:240–245
2. Putzki N, Yaldizli O, Maurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V (2010) Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 17:31–37
3. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O’Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256:405–415
4. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910
5. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870–1880
6. Sorensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18:143–152
7. Borriello G, Prosperini L, Mancinelli C, Gianni C, Fubelli F, Pozzilli C (2012) Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 19:783–787
8. Borriello G, Prosperini L, Marinelli F, Fubelli F, Pozzilli C (2011) Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler 17:372–375
9. Kaufman MD, Lee R, Norton HJ (2011) Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler 17:490–494
10. Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH (2010) Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 68:392–395
11. West TW, Cree BA (2010) Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 68:395–399
12. Magraner MJ, Coret F, Navarre A, Bosca I, Simo M, Escutia M, Bernad A, Navarro L, Casanova B (2011) Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 258:1805–1811
13. Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, Hohlfeld R, Kumpfel T (2011) De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 258:1665–1669
14. Rossi S, Motta C, Studer V, De Chiara V, Barbieri F, Monteleone F, Fornasiero A, Coarelli G, Bernardi G, Cutter G, Stuve O, Salvetti M, Centonze D (2013) Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol 20:87–94
15. Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G (2011) Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 308:98–102
16. Miravalle A, Jensen R, Kinkel RP (2011) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 68:186–191
17. O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76:1858–1865
18. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70:1150–1151
19. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P (2012) Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 18:1640–1643
20. Sempere AP, Martin-Medina P, Berenguer-Ruiz L, Perez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E (2013) Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand 128:e6–e10
21. Rigau V, Mania A, Befort P, Carlander B, Jonquet O, Lassmann H, Camu W, Thouvenot E (2012) Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 79:2214–2216
22. Lenhard T, Biller A, Mueller W, Metz I, Schonberger J, Wildemann B (2010) Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 75:831–833
23. Hellwig K, Gold R (2011) Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 76:1362–1363
24. Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radu EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK (2009) Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72:396–401
25. Fox RJ, Cree B, De Seze J, Gold R, Hartung H-P, Jeffery D, Kappos L, Kaufman M, Montalban X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P (2014) MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 82:1491–1498
26. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O’Connor PW (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23
27. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O’Neill GN (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372(9648):1463–1472
28. Centonze D, Rossi S, Rinaldi F, Gallo P (2012) Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 79:2004–2005
29. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, Palace J, Sharrack B, Swingler R, Young C, Moseley IF, Macmanus DG, Donoghue S, Miller DH (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53:466–472
30. Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A (2012) Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol 19:1060–1069
31. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdova E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O’Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radu EW, Sorensen PS, King J (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10:745–758
32. Dong-Si T, Richman S, Bloomgren G, Wenten M, Philip J, Datta S, McIninch M, Bozic C, Ticho B, Richert N (2013) Survival and functional outcome in asymptomatic natalizumab-associated progressive multifocal leukoencephalopathy multiple sclerosis patients. Mult Scler 19(suppl 1):397 (P879)